TR200605472T1 - AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ - Google Patents
AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@Info
- Publication number
- TR200605472T1 TR200605472T1 TR2006/05472T TR200605472T TR200605472T1 TR 200605472 T1 TR200605472 T1 TR 200605472T1 TR 2006/05472 T TR2006/05472 T TR 2006/05472T TR 200605472 T TR200605472 T TR 200605472T TR 200605472 T1 TR200605472 T1 TR 200605472T1
- Authority
- TR
- Turkey
- Prior art keywords
- receptors
- treatment
- receptor
- increased
- diseases caused
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940075993 receptor modulator Drugs 0.000 title abstract 2
- 101710124361 Arylamine N-acetyltransferase 2 Proteins 0.000 title 2
- 101150116411 AGTR2 gene Proteins 0.000 abstract 2
- 101150059573 AGTR1 gene Proteins 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Buluş, sub-epitelial alandaki AT1 reseptörlerinin artışı veya epiteliadaki AT2 reseptörlerinin artışının neden olduğu hastalıkların ya da durumların tedavisi için farmasötik bir preparasyon üretmek amacıyla sırasıyla bir AT1 reseptör antagonistinin ya da bir AT2 reseptör modulatörünün ya da onun farmasötik olarak uygun bir tuzunun kullanımı ile ilgilidir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98811257 | 1998-12-23 | ||
EP98811258A EP1013273A1 (en) | 1998-12-23 | 1998-12-23 | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200605472T1 true TR200605472T1 (tr) | 2007-02-21 |
Family
ID=26152118
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01784T TR200101784T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı. |
TR2006/05472T TR200605472T1 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ |
TR2006/05471T TR200605471T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
TR2008/05275T TR200805275T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ |
TR2008/05741T TR200805741T2 (tr) | 1998-12-23 | 1999-12-22 | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
TR2002/00764T TR200200764T2 (tr) | 1998-12-23 | 1999-12-22 | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı |
TR2008/05740T TR200805740T1 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01784T TR200101784T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı. |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2006/05471T TR200605471T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
TR2008/05275T TR200805275T2 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ |
TR2008/05741T TR200805741T2 (tr) | 1998-12-23 | 1999-12-22 | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
TR2002/00764T TR200200764T2 (tr) | 1998-12-23 | 1999-12-22 | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı |
TR2008/05740T TR200805740T1 (tr) | 1998-12-23 | 1999-12-22 | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ |
Country Status (26)
Country | Link |
---|---|
EP (3) | EP1140071B1 (tr) |
JP (2) | JP2002533390A (tr) |
KR (1) | KR100646716B1 (tr) |
CN (2) | CN1304000C (tr) |
AT (2) | ATE354364T1 (tr) |
AU (4) | AU3043000A (tr) |
BR (1) | BR9916576A (tr) |
CA (2) | CA2351357A1 (tr) |
CY (2) | CY1106581T1 (tr) |
CZ (2) | CZ293257B6 (tr) |
DE (1) | DE69935249T2 (tr) |
DK (2) | DK1588706T3 (tr) |
ES (2) | ES2281978T3 (tr) |
HK (1) | HK1038888B (tr) |
HU (1) | HUP0104780A3 (tr) |
ID (1) | ID29856A (tr) |
IL (5) | IL143233A0 (tr) |
NO (2) | NO328775B1 (tr) |
NZ (3) | NZ511938A (tr) |
PL (1) | PL199100B1 (tr) |
PT (2) | PT1588706E (tr) |
RU (3) | RU2271809C2 (tr) |
SI (2) | SI1140071T1 (tr) |
SK (1) | SK9132001A3 (tr) |
TR (7) | TR200101784T2 (tr) |
WO (1) | WO2000038676A1 (tr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK18062002A3 (sk) * | 2000-06-22 | 2003-07-01 | Novartis Ag | Pevné orálne farmaceutické kompozície obsahujúce valsartan |
JP4972847B2 (ja) * | 2000-10-11 | 2012-07-11 | 住友化学株式会社 | コラーゲン蓄積抑制剤 |
WO2002083127A1 (fr) * | 2001-04-09 | 2002-10-24 | Tokai University Educational System | Compositions inhibant la modification proteique |
AU2002257970B2 (en) | 2001-05-31 | 2007-08-02 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin II agonists |
WO2003041739A1 (en) | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticaner agents |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
PL382044A1 (pl) * | 2003-11-03 | 2007-08-06 | Zentiva, A.S. | Preparat zawierający walsartan |
EA015108B1 (ru) | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
RS52927B (en) * | 2004-12-24 | 2014-02-28 | Spinifex Pharmaceuticals Pty Ltd | TREATMENT OR PROPHYLAX PROCEDURE |
WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
ES2246742B1 (es) * | 2005-09-06 | 2007-02-01 | Prous Institute For Biomedical Research S.A. | Uso de un derivado de imidazol. |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
CA2681708A1 (en) * | 2007-03-29 | 2008-10-09 | Alembic Limited | Valsartan tablet formulations |
TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
CA2701695A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
PT3067043T (pt) | 2007-11-06 | 2023-03-01 | Novartis Ag | Composições farmacêuticas baseadas em superestruturas de antagonista/bloqueador de receptores da angiotensina (arb) e inibidores da endopeptidase neutra (nep) |
WO2009092052A2 (en) | 2008-01-18 | 2009-07-23 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating polyps |
GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
WO2010104485A2 (en) | 2009-03-11 | 2010-09-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
CN102266307B (zh) * | 2011-08-01 | 2012-10-24 | 海南锦瑞制药股份有限公司 | 一种缬沙坦胶囊及其制备方法 |
WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
US20220257698A1 (en) | 2019-08-02 | 2022-08-18 | Lanthiopep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
WO2024026528A1 (en) * | 2022-08-02 | 2024-02-08 | Dimerix Bioscience Pty Ltd | Dosage regimen for the treatment of copd |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
ATE108996T1 (de) * | 1988-02-25 | 1994-08-15 | Brocades Pharma Bv | Verfahren zur herstellung eines pharmazeutischen granulats. |
CA2018438C (en) | 1989-06-14 | 2000-08-08 | Joseph Alan Finkelstein | Imidazolyl-alkenoic acids |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
DK0443983T3 (da) * | 1990-02-19 | 1996-03-18 | Ciba Geigy Ag | Acrylforbindelser |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
EP0551432A1 (en) * | 1990-10-02 | 1993-07-21 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
DE4038335A1 (de) * | 1990-12-01 | 1992-06-04 | Boehringer Mannheim Gmbh | Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel |
US5614519A (en) * | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DE4132632A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Substituierte imidazolyl-propensaeurederivate |
DE4309968A1 (de) * | 1993-03-26 | 1994-09-29 | Bayer Ag | Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten |
ATE181830T1 (de) | 1992-04-13 | 1999-07-15 | Zeneca Ltd | Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie |
EP0673371A1 (de) | 1992-12-11 | 1995-09-27 | Novartis AG | Benzazepinon-derivate |
AU685767B2 (en) * | 1992-12-11 | 1998-01-29 | Novartis Ag | Substituted benzazepinones |
DE4309963A1 (de) * | 1993-03-26 | 1994-09-29 | Hubert Kamperschroer | Faß zum Austragen von Gülle |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
DE4408497A1 (de) * | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CA2184712A1 (en) | 1994-03-17 | 1995-09-21 | Marc De Gasparo | Treatment of diabetic nephropathy with valsartan |
DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
JPH11513395A (ja) | 1995-10-06 | 1999-11-16 | ノバルティス・アクチエンゲゼルシャフト | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト |
AU2316997A (en) | 1996-02-27 | 1997-09-16 | David H Thompson | Liposomal delivery system |
JP4369994B2 (ja) | 1996-02-29 | 2009-11-25 | ノバルティス アクチエンゲゼルシャフト | アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
DE19628617A1 (de) * | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
CN1234357C (zh) | 1998-07-10 | 2006-01-04 | 诺瓦提斯公司 | 缬沙坦和钙通道阻断剂的抗超敏组合 |
ID29818A (id) * | 1999-01-26 | 2001-10-11 | Novartis Ag | Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial |
SK18062002A3 (sk) * | 2000-06-22 | 2003-07-01 | Novartis Ag | Pevné orálne farmaceutické kompozície obsahujúce valsartan |
WO2005039637A2 (en) | 2003-10-17 | 2005-05-06 | Novartis Ag | Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker |
JP2009018990A (ja) | 2005-10-25 | 2009-01-29 | Univ Kurume | C型肝炎ウイルス由来ペプチド |
-
1999
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/tr unknown
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/tr unknown
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/tr unknown
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 EP EP99964665A patent/EP1140071B1/en not_active Revoked
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/tr unknown
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/tr unknown
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/tr unknown
- 1999-12-22 EP EP10010334A patent/EP2298298A3/en not_active Withdrawn
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/en active IP Right Grant
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/tr unknown
- 1999-12-22 EP EP05013209A patent/EP1588706B1/en not_active Revoked
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active IP Right Cessation
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 CA CA002351357A patent/CA2351357A1/en not_active Abandoned
- 1999-12-22 CA CA2622805A patent/CA2622805C/en not_active Expired - Fee Related
-
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
-
2002
- 2002-01-28 HK HK02100661.6A patent/HK1038888B/zh not_active IP Right Cessation
-
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
-
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
-
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
-
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
-
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
-
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
-
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200605472T1 (tr) | AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@ | |
BR0010215A (pt) | Derivados de indolina como antagonistas de progesterona | |
BG66085B1 (bg) | Фенилаланинови производни | |
GC0000375A (en) | Benzodiazepine derivatives as gaba a receptor modulators | |
ATE505208T1 (de) | Rezeptorbindende konjugate | |
BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
ATE353875T1 (de) | Indolderivate | |
TR200000792T2 (tr) | Vitronektin reseptör antagonistleri. | |
AP1402A (en) | Prevention of migraine recurrence. | |
DE60028928D1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
PT883401E (pt) | Antagonista do receptor at1 para estimulacao da apoptose | |
TR200103827T2 (tr) | Farmakolojik kompleks | |
PT1143942E (pt) | Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas | |
MY131858A (en) | Active ingredient combination for the pharmacological therapy of nicotine dependence | |
HUP9900606A2 (hu) | 5-HT3 Receptor antagonisták mozgászavar kezelésére |